Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.44 |
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.44 |
| ▸ | CPB1 | P15086 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | ABAT | P80404 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.31 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.31 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6365923 | 1.00 | TSHR (0.59) | TSHRKDM4EGRIK1GRIK2LDHA | |
| SCHEMBL33410 | 1.00 | TSHR (0.59) | TSHRKDM4EGRIK1GRIK2LDHA | |
| SCHEMBL7076812 | 0.97 | TSHR (0.56) | TSHRKDM4EGRIK1GRIK2LDHA | |
| Ammonia Solution, Strong SCHEMBL28249079 | 0.97 | TSHR (0.56) | TSHRKDM4EGRIK1GRIK2LDHA | |
| SCHEMBL11743391 | 0.97 | TSHR (0.56) | TSHRKDM4EGRIK1GRIK2LDHA | |
| Hydrochloric Acid SCHEMBL28241597 | 0.95 | TSHR (0.54) | TSHRKDM4EGRIK1GRIK2LDHA | |
| SCHEMBL27804216 | 0.88 | TSHR (0.48) | TSHRKDM4EGRIK1GRIK2LDHA | |
| Acrylic Acid SCHEMBL29198707 | 0.88 | ALOX15 (0.56) | TSHRKDM4EGRIK1GRIK2LDHA | |
| Itaconate SCHEMBL10984223 | 0.86 | ALOX15 (0.59) | TSHRKDM4EGRIK1GRIK2LDHA | |
| Dimethyl Fumarate SCHEMBL5077436 | 0.84 | HCAR2 (0.54) | TSHRKDM4EGRIK1GRIK2LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291986-A1 | ITACONIC ACID AND ITACONATE METHYLESTER PRODUCTION | DSM IP ASSETS B.V. (NL) | 2015-10-15 | — | — | US | disclosed |
| US-8404738-B2 | 4-amino-N-hydroxy-benzamides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404738-B2 | 4-amino-N-hydroxy-benzamides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2013-03-26 | — | — | US | disclosed |
| WO-2012162175-A1 | EMETINE DERIVATIVES, PRODRUGS CONTAINING SAME, AND METHODS OF TREATING CONDITIONS USING SAME | HOWARD UNIVERSITY (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120190700-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. | 2012-07-26 | — | — | US | disclosed |
| US-20120190700-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. | 2012-07-26 | — | — | US | disclosed |
| WO-2012098132-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES AS HDAC INHIBITORS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-26 | — | — | WO | disclosed |
| US-8124174-B2 | Electroless gold plating method and electronic parts | C. UYEMURA & CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-7511023-B2 | adriamycin; chemotherapy; sustained release | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-03-31 | — | — | US | disclosed |
| US-20080277140-A1 | ELECTROLESS GOLD PLATING METHOD AND ELECTRONIC PARTS | C. UYEMURA & CO., LTD. (JP) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190700-A1 | NOVEL 4-AMINO-N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | HRH4, H1-4, HNMT | TSHR 1863/4885KDM4E 47/4885GRIK1 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.